An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients

Susanna Esposito1, Elisa Meregalli2, Cristina Daleno1, Luciana Ghio2, Claudia Tagliabue1, Antonia Valzano1, Domenico Serra1, Carlotta Galeone3,4, Alberto Edefonti2 and Nicola Principi

1Department of Maternal and Pediatric Sciences, Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, 2Pediatric Nephrology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, 3Department of Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, and 4Department of Occupational Health “Clinica del Lavoro Luigi Devo”, Section of Medical Statistics “Giulio A. Maccacaro”, Università degli Studi di Milano, Milan, Italy

Correspondence and offprint requests to: Nicola Principi; E-mail: Nicola.principi@unimi.it

Abstract

Background. The aim of this study was to investigate the immunogenicity, safety and tolerability of the 2009 A/H1N1 MF59-adjuvanted influenza vaccine, administered sequentially or simultaneously with the seasonal 2009–10 virosomal-adjuvanted influenza vaccine, to paediatric kidney transplant recipients.

Methods. Thirty-two children and adolescents with transplanted kidneys and 32 age- and gender-matched healthy controls were randomized 1:1 to receive the pandemic vaccine upon enrolment and the seasonal vaccine 1 month later (16 transplant recipients and 16 healthy controls), or to receive the two vaccines simultaneously upon enrolment (16 transplant recipients and 16 healthy controls).

Results. When the pandemic vaccine was administered sequentially to the seasonal vaccine, it was significantly less immunogenic in the patients than in the controls (P < 0.05); when it was administered together with the seasonal vaccine, the immune response of both patients (P < 0.05) and controls (P < 0.05) was significantly greater than when it was administered sequentially. Seroconversion rates and the geometric mean titres of all of the seasonal antigens were significantly lower in the patients, regardless of the type of vaccine administration (P < 0.05). Simultaneous administration was associated with a better immune response against A/H1N1 and A/H3N2 antigens in both patients and controls, and did not increase the mild local and systemic reactions. No impact on renal function was observed.

Conclusions. Paediatric kidney transplant recipients have a lower immune response to the pandemic influenza A/H1N1 MF59-adjuvanted and seasonal virosomal-adjuvanted influenza vaccines than healthy controls. The simultaneous administration of the two vaccines seems to increase immune response to both pandemic and seasonal A/H1N1 and A/H3N2 antigens, and has the same safety profile as that of the pandemic vaccine administered sequentially to the seasonal vaccine.

Keywords: A/H1N1 influenza vaccine; kidney transplantation; pandemic influenza; paediatrics; seasonal influenza vaccine

Introduction

Not only influenza has been associated with acute kidney allograft rejection [1], but also kidney transplant recipients are at higher risk of experiencing severe infection because of the potent immunosuppressive therapy they receive to prevent the rejection itself [2,3]. Consequently, also considering that recent literature does not support the concerns that vaccination may trigger rejection [4], it is strongly recommended that kidney transplant recipients be included in the list of subjects who should be administered the seasonal trivalent-inactivated vaccine against influenza viruses every year [5,6]. However, there are conflicting reports concerning the immunogenicity and efficacy of the vaccine in such patients [7–13].

In April 2009, the emergence of influenza virus A/H1N1 in humans caused the first influenza pandemic since 1968 [14] and led to the preparation of various specific vaccines with or without adjuvant [15]. Immunosuppressed patients (including kidney transplant recipients) were included among the subjects having a right to priority immunization [16,17], but this decision was not supported by any specific studies of the vaccines’ immunogenicity,
Influenza vaccines in kidney transplant recipients

Materials and methods

Study population

This open-label study, which started on 1 November 2009, involved 32 paediatric kidney transplant recipients who were being regularly followed up at the outpatient clinic of the Pediatric Nephrology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, and who had never previously been vaccinated against seasonal influenza. As the pandemic A/H1N1 influenza vaccine only became available in Italy 4–2 weeks after the first documented episode of pandemic influenza, the transplant recipients who had experienced an influenza-like illness in 4 weeks preceding the start of the study were excluded in order to avoid the risk of enrolling already infected subjects. The control group consisted of the same number of healthy age- and gender-matched subjects selected using the same criteria and enrolled sequentially among those who attended the outpatient clinic for a control visit after a previous hospitalization for minor surgical problems.

The members of each group were randomly assigned 1:1 on the basis of a computer-generated randomization list to receive the pandemic vaccine upon enrolment and the seasonal vaccine 4 weeks (28 ± 2 days) later, or to receive the two vaccines simultaneously upon enrolment.

The study was approved by the Ethics Committee of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, and written informed consent was obtained from the patients’ parents or legal guardians, and from the patients themselves.

Vaccines

The pandemic vaccine was the monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine Focetria (Novartis, Siena, Italy); each 0.5-mL dose contained 7.5 μg of H1 haemagglutinin, 9.75 mg of the squalene MF59, 1.175 mg of polysorbate 80 and 1.175 mg of sorbitan trioleate in buffer. The seasonal vaccine was the 2009–10 virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients.

Procedures

Between 1 November 2009 and 15 November 2009, all of the enrolled subjects underwent a baseline assessment that included recording of demographic and medical history data, and a physical examination. Demographic data of each transplant recipient included the type of graft donor, the number of transplants, the aetiology of end-stage primary renal disease, the time interval between transplantation and vaccination, and the immunosuppressive regimen. Blood samples were drawn from all of the children at enrolment, and 4 weeks (28 ± 2 days) and 8 weeks (56 ± 2 days) after each vaccine administration, to evaluate immunogenicity and blood urea nitrogen (BUN) and creatinine concentrations; at the same visits, a urine sample was collected for complete laboratory analysis.

The pandemic vaccine was injected into the left deltoid muscle and the seasonal vaccine in the right deltoid muscle, regardless of the time of administration.

The subjects were observed for 30 min after the injection, and they or their parents recorded the occurrence of solicited and unsolicited local symptoms (erythema, swelling/induration and pain) or systemic symptoms (an axillary temperature of ≥38°C, irritability, sleepiness, changes in eating habits, vomiting, diarrhea, malaise and muscle aches) for the next 14 days. The symptoms were considered mild if they did not interfere with normal everyday activities, and severe if they prevented them and required medical attention. Adverse reactions were defined as any reaction that persisted for longer than 7 days after the vaccination, and serious adverse reactions as any reaction that required medical attention or hospitalization during the study period.

The subjects and their parents were asked to pay particular attention to the development of symptoms resembling influenza-like illness throughout the study period and, if these appeared, to return immediately to the study centre for clinical evaluation and laboratory testing of nasal swabs for influenza viruses [19]. Further data regarding the clinical events that occurred between vaccine administrations were collected during the visits made for vaccine administration and/or blood collection.

Immunogenicity was evaluated by measuring haemagglutination-inhibiting (HI) antibodies to the influenza strains contained in the vaccines using standard assays [20]. The serum samples were tested in duplicate at an initial dilution of 1:10, and those that were negative for the antibody were assigned an arbitrary titre of 1:5. HI antibody titres were expressed as the reciprocal of the highest serum dilution that completely inhibited haemagglutination.

Humoral immune response was assessed on the basis of the seroconversion rate (defined as the percentage of subjects experiencing at least a 4-fold increase in a seropositive pre-vaccination HI antibody titre, or an increase from <10 to ≥40 in those who were seronegative), geometric mean titres (GMTs), the difference between the mean pre- and post-vaccination titres, and the seroprotection rate (defined as the percentage of subjects reaching an HI titre of ≥40).

Statistical analysis

Comparisons were made between the kidney transplant recipients and the healthy controls, and between the groups vaccinated sequentially or simultaneously. With a 5% type 1 error rate and a power of 90%, 16 transplant recipients and 16 healthy controls were required to show a difference of 50% in immunogenicity.

Continuous variables are expressed as mean values ± standard deviation (SD), and categorical variables as numbers and percentages. The continuous data were analysed using Student’s t-test if they were normally distributed (on the basis of the Shapiro–Wilk statistic) or a Wilcoxon rank-sum test if they were not. The categorical data were analysed using contingency tables and the chi-square or Fisher’s test, as appropriate. All of the analyses were two-tailed, and P-values of <0.05 were considered significant.

Results

Study population

Table 1 shows the demographic and clinical characteristics of the study population. Thirty-two kidney transplant recipients (20 males; mean age ± SD 15.5 ± 5.5 years) all received kidneys from deceased donor and underwent only one transplant. The most frequent cause of the end-stage renal disease (>50%) leading to transplantation was congenital kidney and urinary tract anomalies. The mean time between transplantation and vaccination was 94.7 ± 63.4 months. More than 80% of the cases were receiving calcineurin inhibitor-based immunosuppressive treatment.
All the patients had received induction therapy with basiliximab after transplantation. Sixteen of the subjects in both groups received the pandemic vaccine upon enrolment and the seasonal vaccine 4 weeks later; the other 16 in both groups received both vaccines at the same time.

None of the subjects in either group had a history of influenza-like illness since May 2009 (date of circulation of pandemic influenza A/H1N1 virus in Europe) or experienced an episode of laboratory-confirmed pandemic or seasonal influenza during the study period.

### Immune response

Table 2 shows the data regarding the immunogenicity of the monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered simultaneously with, or 1 month before the seasonal vaccine. Some of the subjects

| Characteristic | Pandemic vaccine alone followed by seasonal vaccine alone | Pandemic vaccine + seasonal vaccine |
|---------------|----------------------------------------------------------|-----------------------------------|
|               | Transplant recipients (n = 16) | Healthy controls (n = 16) | Transplant recipients (n = 16) | Healthy controls (n = 16) |
| Age (years), mean ± SD | 15.4 ± 5.6 | 15.6 ± 5.5 | 15.7 ± 5.5 | 15.4 ± 5.7 |
| Males, n (%) | 10 (62.5) | 10 (62.5) | 10 (62.5) | 10 (62.5) |
| Caucasians, n (%) | 13 (81.3) | 13 (81.3) | 12 (75.0) | 12 (75.0) |
| Antibiotic treatment in previous 3 months, n (%) | 1 (6.3) | 1 (6.3) | 1 (6.3) | 1 (6.3) |
| Primary renal disease, n (%) | 9 (56.3) | NA | 9 (56.3) | NA |
| Congenital anomalies of the kidney and urinary tract | 1 (6.3) | NA | 3 (18.7) | NA |
| Congenital nephritic syndrome | 2 (12.5) | NA | 0 (0.0) | NA |
| Neurological bladder | 1 (6.3) | NA | 1 (6.3) | NA |
| Intestinal nephritis | 1 (6.3) | NA | 1 (6.3) | NA |
| Kidney thrombosis | 0 (0.0) | NA | 1 (6.3) | NA |
| Wilms' tumour | 0 (0.0) | NA | 1 (6.3) | NA |
| Haemolytic uraemic syndrome | 1 (6.3) | NA | 0 (0.0) | NA |
| Cortical necrosis | 1 (6.3) | NA | 0 (0.0) | NA |
| Time between transplant and vaccines, months (mean ± SD) | 96.9 ± 78.7 | NA | 93.6 ± 53.4 | NA |
| Immunosuppressive regimens, n (%) | | | | |
| Tacrolimus-based | 10 (62.5) | NA | 9 (56.3) | NA |
| Cyclosporine-based | 4 (25.0) | NA | 4 (25.0) | NA |
| Sirolimus-based | 2 (12.5) | NA | 3 (18.7) | NA |
| Hospitalized in previous 3 months, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Previously administered seasonal influenza vaccine, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |

No significant between-group difference. NA, not applicable.

(tacrolimus or cyclosporine). All the patients had received induction therapy with basiliximab after transplantation.

Sixteen of the subjects in both groups received the pandemic vaccine upon enrolment and the seasonal vaccine 4 weeks later; the other 16 in both groups received both vaccines at the same time.

None of the subjects in either group had a history of influenza-like illness since May 2009 (date of circulation of pandemic influenza A/H1N1 virus in Europe) or experienced an episode of laboratory-confirmed pandemic or seasonal influenza during the study period.

### Immunogenicity end points against the 2009 pandemic A/H1N1 influenza strain in kidney transplant recipients and healthy controls

#### Table 2

| Values and timelines | Pandemic vaccine alone followed by seasonal vaccine alone | Pandemic vaccine + seasonal vaccine |
|----------------------|----------------------------------------------------------|-----------------------------------|
|                      | Transplant recipients (n = 16) | Healthy controls (n = 16) | Transplant recipients (n = 16) | Healthy controls (n = 16) |
| Seroconversion, n (%) | | | | |
| Baseline | NA | NA | NA | NA |
| 28 ± 2 days post-Dose 1 | 4 (25.0)* | 16 (100.0) | 15 (93.8)^ | 15 (100.0) |
| GMT (fold increase) | 31.56 (NA) | 44.16 (NA)* | 38.75 (NA)* | 57.63 (NA)* |
| Baseline | 48.13 (25.0) | 270.33 (6.1) | 426.30 (11.0)^ | 630.71 (10.9) |
| 56 ± 2 days post-Dose 1 | 46.25 (1.5)* | 291.82 (6.6) | 530.0 (13.7)^ | 643.10 (11.2) |
| Seroprotection, n (%) | | | | |
| Baseline | 5 (31.2) | 7 (43.7)* | 6 (37.5)* | 7 (43.7)* |
| 28 ± 2 days post-Dose 1 | 10 (62.5) | 16 (100.0) | 15 (93.8) | 16 (100.0) |
| GMT, geometric mean titres; NA, not applicable. *P < 0.05 vs healthy controls administered pandemic vaccine alone followed by seasonal vaccine alone. ^P < 0.05 vs 28 ± 2 days post-Dose 1 and vs 56 ± 2 days post-Dose 1. ^P < 0.05 vs transplant recipients administered pandemic vaccine alone followed by seasonal vaccine alone. | | | | |
The results of this study show that, especially when administered separately, the pandemic and seasonal influenza vaccines are less immunogenic in pediatric kidney transplant recipients receiving mainly calcineurin-immunosuppressive therapy than in healthy subjects even when they are given several after transplantation.

Table 3. Immunogenicity end points against seasonal strains in kidney transplant recipients and healthy controls

| Values and timelines | Pandemic vaccine alone followed by seasonal vaccine alone | Pandemic vaccine + seasonal vaccine |
|----------------------|----------------------------------------------------------|-----------------------------------|
|                      | A/H1N1 (n = 16) A/H3N2 B                              | A/H1N1 (n = 16) A/H3N2 B            |
| Seroconversion, n (%)|                                                           |                                   |
| Baseline             | 2 (12.5)^r 2 (12.5)^r 0 (0.0)^r                        | 4 (25.0)^* 4 (25.0)^* 3 (18.8)^*  |
| 28 ± 2 days post-dose| 14 (87.5) 14 (87.5) 14 (87.5)                        | 15 (93.8) 15 (93.8) 15 (93.8)      |
| 56 ± 2 days post-dose| 15 (93.8) 15 (93.8) 15 (93.8)                        | 15 (93.8) 15 (93.8) 15 (93.8)      |
| GMT (fold increase)  |                                                           |                                   |
| Baseline             | 27.81 (NA) 28.13 (NA) 22.81 (NA)                      | 32.5 (NA)^# 47.81 (NA) 13.13 (NA)  |
| 28 ± 2 days post-dose| 233.69 (9.1) 25.82 (NA) 57.61 (NA)                   | 268.88 (2.0)* 109.38 (4.4) 84.38 (1.8)* |
| 56 ± 2 days post-dose| 249.36 (9.7) 28.75 (1.3)^r 28.75 (1.3)^r           | 117.61 (3.6)* 25.25 (1.3)^r 58.19 (3.7) |
| Seroconversion, n (%)|                                                           |                                   |
| Baseline             | 5 (31.3) 5 (31.3) 2 (12.5)                            | 6 (37.5) 6 (37.5) 1 (6.3)          |
| 28 ± 2 days post-dose| 7 (43.8) 8 (50.0) 4 (25.0)                            | 11 (68.8) 10 (62.5) 5 (31.3)       |
| 56 ± 2 days post-dose| 7 (43.8) 8 (50.0) 5 (31.3)                            | 15 (93.8) 15 (93.8) 15 (93.8)      |

NA, not applicable. ^P < 0.05 vs healthy controls administered pandemic vaccine alone followed by seasonal vaccine alone. °P < 0.05 vs transplant recipients administered pandemic vaccine + seasonal vaccine. *P < 0.05 vs healthy controls administered pandemic vaccine + seasonal vaccine. #P < 0.05 vs 28 ± 2 days post-dose 1 and vs 56 ± 2 days post-dose 1. 0P < 0.05 vs transplant recipients administered pandemic vaccine alone followed by seasonal vaccine alone.
However, the immune response to the pandemic antigen is greater than that to the seasonal antigens, as demonstrated by the larger number of subjects achieving seroprotection and the higher GMTs 4 and 8 weeks after immunization, despite the fact that the antigen concentration in the pandemic MF59-adjuvanted vaccine was half the usual concentration of each of the antigens in traditional seasonal vaccines. It is unlikely that this effect was attributable to previous or concomitant infection with the wild pandemic virus because the GMTs also increased in the subjects without serum-detectable immunity at the time of enrolment, and because careful clinical monitoring of both patients and controls reduced the possibility of a response due to an infection occurring during the study period. In our opinion, it may have been related to the more immunogenic nature of the 2009 influenza A/H1N1 haemagglutinin [21–24] and the fact that the pandemic vaccine contained MF59, an adjuvant that can significantly increase immune responses to influenza antigens even in young patients in whom they are known to be weaker [25,26].

The very low immune response evoked by the seasonal vaccine is in line with the findings of other authors showing that transplant patients have impaired immune responses to a number of vaccines (including seasonal influenza vaccine), particularly when they are receiving calcineurin

| Local reactions, n (%) | Sequential vaccine administrations | Simultaneous vaccine administrations |
|-----------------------|-----------------------------------|------------------------------------|
|                       | Pandemic alone | Seasonal alone | Pandemic + seasonal |
|                       | Transplant recipients (n = 16) | Healthy controls (n = 16) | Transplant recipients (n = 16) | Healthy controls (n = 16) | Transplant recipients (n = 16) | Healthy controls (n = 16) |
| Erythema              | 0 (0.0)         | 1 (6.3)         | 1 (6.3)         | 1 (6.3)         | 1 (6.3)         | 1 (6.3)         |
| Swelling/induration   | 3 (18.8)        | 2 (12.5)        | 2 (12.5)        | 2 (12.5)        | 4 (25.0)        | 2 (12.5)        |
| Pain                  | 3 (18.8)        | 2 (12.5)        | 2 (12.5)        | 2 (12.5)        | 4 (25.0)        | 2 (12.5)        |
| At least one local event | 4 (25.0)    | 4 (25.0)        | 3 (18.8)        | 3 (18.8)        | 4 (25.0)        | 3 (18.8)        |
| Systemic reactions, n (%) |
| Fever ≥38°C            | 1 (6.3)         | 1 (6.3)         | 0 (0.0)         | 1 (6.3)         | 1 (6.3)         | 1 (6.3)         |
| Rhinitis              | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         |
| Malaise               | 1 (6.3)         | 0 (0.0)         | 1 (6.3)         | 1 (6.3)         | 1 (6.3)         | 1 (6.3)         |
| Sleepiness            | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         |
| Changed eating habits | 0 (0.0)         | 1 (6.3)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         |
| Vomiting              | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         |
| Diarrhoea             | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         |
| At least one systemic event | 2 (12.5) | 2 (12.5)        | 1 (6.3)         | 2 (12.5)        | 2 (12.5)        | 2 (12.5)        |
| At least one local or systemic event | 4 (25.0) | 4 (25.0)        | 3 (18.8)        | 4 (25.0)        | 5 (31.3)        | 4 (25.0)        |
| Required drugs for local or systemic events | 2 (12.5) | 1 (6.3)         | 1 (6.3)         | 1 (6.3)         | 3 (18.8)        | 2 (12.5)        |
| Serious adverse events | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         | 0 (0.0)         |
| Percentages in parentheses. No significant differences between the transplant recipients and healthy controls.

However, the immune response to the pandemic antigen is greater than that to the seasonal antigens, as demonstrated by the larger number of subjects achieving seroprotection and the higher antigen GMTs 4 and 8 weeks after immunization, despite the fact that the antigen concentration in the pandemic MF59-adjuvanted vaccine was half the usual concentration of each of the antigens in traditional seasonal vaccines. It is unlikely that this effect was attributable to previous or concomitant infection with the wild pandemic virus because the GMTs also increased in the subjects without serum-detectable immunity at the time of enrolment, and because careful clinical monitoring of both patients and controls reduced the possibility of a response due to an infection occurring during the study period. In our opinion, it may have been related to the more immunogenic nature of the 2009 influenza A/H1N1 haemagglutinin [21–24] and the fact that the pandemic vaccine contained MF59, an adjuvant that can significantly increase immune responses to influenza antigens even in young patients in whom they are known to be weaker [25,26].

The very low immune response evoked by the seasonal vaccine is in line with the findings of other authors showing that transplant patients have impaired immune responses to a number of vaccines (including seasonal influenza vaccine), particularly when they are receiving calcineurin

### Table 5. Impact on renal function in the months following vaccination with the 2009 pandemic A/H1N1 MF59-adjuvanted influenza vaccine administered together with or 1 month before the seasonal virosomal-adjuvanted influenza vaccination to kidney transplant recipients

| Laboratory data | Baseline | 1 month after vaccination | 3 months after vaccination |
|-----------------|---------|--------------------------|--------------------------|
| BUN, mg/dL      | Sequential group Transplant recipients (n = 16) | Simultaneous group Transplant recipients (n = 16) | Sequential group Transplant recipients (n = 16) | Simultaneous group Transplant recipients (n = 16) |
| Mean values ± SD | 61.0 ± 28.9 | 63.5 ± 22.6 | 61.5 ± 29.3 | 63.1 ± 21.7 | 61.3 ± 29.1 | 63.3 ± 22.3 |
| Serum creatinine, mg/dL | 1.29 ± 0.53 | 1.43 ± 0.69 | 1.27 ± 0.53 | 1.38 ± 0.77 | 1.30 ± 0.49 | 1.40 ± 0.58 |
| Proteinuria, mg/day | 125 ± 25 | 119 ± 30 | 128 ± 24 | 120 ± 28 | 133 ± 24 | 113 ± 39 |
| Proteinuria/creatininuria | 0.10 | 0.11 | 0.11 | 0.13 | 0.9 | 0.14 |
| Haematuria, n. (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |

Percentages in parentheses. No significant differences between baseline, 1 month and 3 months after vaccination. BUN, blood urea nitrogen.
inhibitor-based immunosuppressive therapy like our patients [11–13,27]. However, it is unlikely that induction therapy received after transplantation has influenced the vaccine response, because all the patients received it several months before the study and, in other conditions like cancer, it has been demonstrated that the strong effect of induction therapy is finished a few months after its end [28].

Moreover, all of our patients received basiliximab as induction therapy, and it is known that the long-term effects of this drug are lower than that of thymoglobulin [29,30].

Interestingly, the immune response of both patients and controls to the MF59-adjuvanted pandemic vaccine was significantly increased by its simultaneous administration with the seasonal virosomal-adjuvanted vaccine. In this case, the response of the transplant recipients was quite similar to that of the healthy subjects, leading to optimal seroconversion and seroprotection rates, and GMTs that were high enough to suggest long-term protection. The incremental effect of simultaneous administration also extended to the seasonal A/H1N1 and A/H3N2 antigens, although the response of the transplant recipients remained significantly weaker than that of the healthy subjects and cannot be considered satisfactory. In this regard, our findings are different from those of Vaio et al. that did not observe any increase in immune responses when the pandemic and seasonal influenza vaccines were administered together [31]. Their data are not directly comparable with ours because they used a pandemic vaccine containing a different adjuvant and lower antigen levels and a non-adjuvanted seasonal vaccine. Nevertheless, one possible reason for the difference is our simultaneous administration of two adjuvants. In that regard, the interaction between MF59 and virosomal adjuvants has been nicely described in a mouse model by Radosevic et al. [32]. Another possible explanation is the fact that, although different, the pandemic and seasonal influenza A viruses have some genetic similarities, and so, their simultaneous administration may lead to greater antigen stimulation [33]. However, it is not clear why the additive effect should be more pronounced for the pandemic than the seasonal vaccine.

Genetic similarities between the pandemic A/H1N1 and the seasonal A/H1N1 viruses may explain why a part of the study population had measurable specific antibody titres against the pandemic virus at baseline. On the other hand, although subclinical infections are possible, our study patients had no history of influenza-like illness possibly related to the pandemic virus, but considering their mean age, all of them had probably had previous history of seasonal influenza infection. This finding is in line with the data showing that population was not fully naïve to the current pandemic virus [34] and that cross-reactivity of HI antibodies is possible between pandemic A/H1N1 and seasonal A/H1N1 viruses [33].

The fact that none of our study patients had been previously vaccinated against seasonal influenza, despite the fact that transplant recipients are included among the high-risk groups for whom influenza vaccination is recommended, is not surprising and is in line with our previous data showing a very low influenza vaccination coverage among Italian high-risk categories [35].

The seasonal vaccine specifically prepared for the 2010–11 influenza season contains the pandemic antigen and the seasonal A/H3N2 and B virus antigens, but as it will not be adjuvanted (or will contain only a single adjuvant), it is difficult to foresee whether it will lead to an additive effect against the pandemic A/H1N1 antigen or whether it will adequately protect kidney transplant recipients. Consequently, given their weaker immune response in comparison with healthy controls, they need to be vaccinated and also closely monitored for influenza-like illness during the influenza period [36].

We found that the safety and tolerability of both the MF59-adjuvanted pandemic vaccine and the seasonal virosomal-adjuvanted vaccine were good in all of our study subjects, and their simultaneous administration did not increase the incidence of solicited and unsolicited local or systemic reactions in either group. Furthermore, our monitoring of the markers of renal function and the urinalyses did not reveal any signs that the pandemic vaccine might be associated with kidney graft rejection even when it was administered together with the seasonal vaccine.

In conclusion, our data indicate that the immune response of paediatric kidney transplant recipients to the MF59-adjuvanted pandemic influenza A/H1N1 vaccine and the seasonal virosomal-adjuvanted influenza vaccine is less than that of healthy controls. The simultaneous administration of the two vaccines leads to a statistically significant increase in immune response to the pandemic antigen, and a slightly higher response to seasonal A/H1N1 and A/H3N2 antigens, with no difference in safety profile. Further studies are needed to verify whether the inclusion of the pandemic antigen in the seasonal influenza vaccine specifically prepared for the 2010–11 influenza season improves the immune response of kidney transplant recipients to all influenza virus antigens.

Acknowledgements. This study was supported in part by a grant from the Italian Ministry of Health (Bando Giovani Ricercatori 2007).

Conflict of interest statement. None declared.

References

1. Wendt CH. Community respiratory viruses: organ transplant recipients. Am J Med 1997; 17: 31–36
2. Vilchez RA, McCurry K, Dauber J et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2: 287–291
3. Keane WR, Helderman JH, Luby J et al. Epidemic renal transplant rejection associated with influenza A Victoria. Proc Clin Dial Transplant Forum 1978; 8: 232–236
4. Candon S, Thervet E, Lebon P et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 2009; 9: 2346–2354
5. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 1–68
6. Esposito S, Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr Opin Infect Dis 2009; 22: 244–249
10. Blumberg EA, Albano C, Pruett T et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 10: 556–560

11. Keshtkar-Jahromi M, Argani H, Rahnavardi M. Influenza virus vaccine in solid organ transplant recipients: a prospective cohort study. Am J Kidney Dis 2009; 54: 112–121

12. Birdwell KA, Ikizler MR, Sannella EC et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: an exploratory study. JAMA 1997; 277: 1267–1271

13. Salles MJC, Sens YAS, Boas LSV et al. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant 2010; 24: E17–E23

14. Kelly H, Barr I. Large trials confirm immunogenicity of H1N1 vaccines. Lancet 2010; 375: 6–9

15. Hahné S, Donker T, Meyer A et al. Epidemiology and control of influenza A(H1N1) in the Netherlands: the first 115 cases. Euro Surveill 2009; 14: pii=9267

16. European CDC. ECDC Health Education. On the use of specific pandemic influenza vaccines. 2010, date last accessed

17. Centers for Disease Control and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58: 1–8

18. Kumar D, Morris MI, Kotton CN et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10: 18–25

19. Esposito S, Molteni CG, Colombo C et al. Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. J Clin Virol 2010; 48: 62–65

20. Menegon T, Baldov B, Bonello C et al. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 1999; 15: 573–576

21. Greenberg ME, Lai MH, Hartel GF et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361: 2405–2413

22. Nolan T, McVernon J, Skeljo M et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303: 37–46

23. Zhu F, Wang H, Fang H et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361: 2414–2423

24. Liang XF, Wang HQ, Wang JZ et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375: 56–66

25. Clark TW, Pareek M, Hoschler K et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361: 2424–2435

26. Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28: 563–571

27. Evison J, Farese S, Seitz M et al. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009; 48: 1402–1412

28. Esposito S, Cecinati V, Scicchitano B et al. Impact of influenza-like illness and effectiveness of influenza vaccination in oncological children who have completed cancer therapy. Vaccine 2009; 28: 1558–1565

29. Anil Kumar MS, Irfan Saeed M, Ranganna K et al. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Transpl Immunol 2008; 20: 32–42

30. Taber DJ, Weinert NA, Henderson F et al. Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation. Transplant Proc 2008; 40: 3401–3407

31. Vajo Z, Tamas F, Sinka L et al. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomized controlled trial. Lancet 2010; 375: 49–55

32. Radosčević K, Rodriguez A, Mintardj C et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine 2008; 26: 3640–3646

33. Hancock K, Veggulla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361: 1945–1952

34. Rizzo C, Rota MC, Bella A et al. Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. Vaccine 2010; 28: 3558–3562

35. Esposito S, Marchisio P, Droghetti R et al. Influenza vaccination coverage among children with high-risk medical conditions. Vaccine 2006; 24: 5251–5255

36. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine. Lancet Infect Dis 2009; 9: 493–504

Received for publication: 20.7.10; Accepted in revised form: 1.10.10